Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
9
|
| pubmed:dateCreated |
1996-1-17
|
| pubmed:abstractText |
Serum interleukin-1 beta (IL-1 beta) and soluble interleukin-2 receptor (sIL-2R) levels were examined in patients with hyperthyroidism due to Graves' disease (GD) and toxic nodular goitre (TNG) before and during antithyroid drug therapy. A total of 32 patients were studied; 23 patients (14 with GD and nine with TNG) were in a hyperthyroid state (group A) and nine patients (four with GD and five with TNG) were in a euthyroid state, under carbimazole or methimazole treatment (group B). Ten hyperthyroid patients from group A (seven with GD and three with TNG) were also examined while euthyroid on treatment (Subgroup A). Serum was taken from all patients for the measurement of sIL-2R, IL-1 beta, total T4 (TT4), total T3 (TT3) and TSH concentrations. The results were compared with those from 30 normal controls. Serum sIL-2R levels were higher in Group A (671.3 +/- 74.0 U mL-1, mean +/- SE), than in Group B (214.1 +/- 61.8 U mL-1) and controls (149 +/- 14.8 U mL-1), P < 0.001. Similarly, the subgroup of 10 patients had higher levels of sIL-2R during the hyperthyroid phase than while euthyroid (P < 0.001). There was a positive correlation between sIL-2R values and levels of T4 and T3. In contrast, serum IL-1 beta levels were higher in Group B patients (197.5 +/- 39.2 pg mL-1) compared with those in Group A (66.5 +/- 17 pg mL-1, P < 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
0014-2972
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
25
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
654-8
|
| pubmed:dateRevised |
2005-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:7498238-Adult,
pubmed-meshheading:7498238-Aged,
pubmed-meshheading:7498238-Antithyroid Agents,
pubmed-meshheading:7498238-Female,
pubmed-meshheading:7498238-Goiter,
pubmed-meshheading:7498238-Graves Disease,
pubmed-meshheading:7498238-Humans,
pubmed-meshheading:7498238-Hyperthyroidism,
pubmed-meshheading:7498238-Interleukin-1,
pubmed-meshheading:7498238-Male,
pubmed-meshheading:7498238-Middle Aged,
pubmed-meshheading:7498238-Receptors, Interleukin-2
|
| pubmed:year |
1995
|
| pubmed:articleTitle |
Increased serum interleukin-1 beta during treatment of hyperthyroidism with antithyroid drugs.
|
| pubmed:affiliation |
Department of Medicine, University of Ioanninia Medical School, Greece.
|
| pubmed:publicationType |
Journal Article
|